Solstice Biologics Closes on $18M

Solstice Biologics, a biotech startup focused on the problem of targeting and delivering nucleic acid therapeutics, has raised $18 million in Series A financing led by venBio and joined by Aeris Capital AG. The company also announced that it has acquired an exclusive license to certain University of California, San Diego intellectual property.

North AmericaUSBriefs